Joakim Nyberg, Ph.D.

Chief Technology Officer

Portrait-of-Joakim-Nyberg-Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, serving as Chief Technology Officer, part of the executive leadership team, leading the Enabler department
  • Expertise includes pharmacometrics, trial design, and systems development
  • Experience as Researcher at Uppsala University, Sweden, where he has a part-time position to perform pharmacometric research, primarily by supervision of Ph.D. students. Previously worked as System Developer at B&M Systemutveckling AB, Sweden
  • M.Sc. in Engineering Physics (2006) and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A structured approach to pharmacometric covariate modelling: why the estimand is the first decision and the method the secondThe use of full random effect models (FREM) in model informed precision dosing (MIPD) for a priori dose predictionsConditional versus unconditional covariate effects in pharmacometric models: implications for interpretation, communication, and reportingSimplifying the Communication of Covariate Effects from Pharmacometric Models – The Role of Unconditional Covariate EffectsUsing Full Random Effects Models (FREM) in different softwareThe impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects modelsThe impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEMFull random effects models (FREM): A practical usage guideGenerating uncertainty estimates in empirical forest plotsUsing forest plots to interpret covariate effects in pharmacometric modelsProperties of the full random-effect modeling approach with missing covariate data